- Merck Receives Two Positive EU CHMP Opinions for KEYTRUDA® (pembrolizumab), for Subcutaneous (SC) Administration and for New Indication for Earlier-Stage Head and Neck Cancer Merck.com
- FDA OKs New Keytruda Shot for Cancer The New York Times
- Pembrolizumab Earns 2 Positive CHMP Opinions in HNSCC, Other EU Indications OncLive
- Merck Receives Positive EU CHMP Opinion for ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) in Infants During Their First RSV Season Business Wire
- Ema’s CHMP recommended five extensions of indication for medicines Bimervax, Dupixent, Keytruda MarketScreener
Source link
